Loading
Putting the CAR gene into T cells without a virus removes the most expensive and delay-prone ingredient. Test whether non-viral products match viral ones.
Transposon systems (piggyBac, Sleeping Beauty) and CRISPR-mediated targeted insertion (for example into the TRAC locus) deliver CAR constructs as DNA or RNA without lentiviral vector, cutting materials cost and removing the vector supply queue; clinical experience exists from Poseida, MD Anderson, Chinese academic groups and others, with an early piggyBac safety signal (lymphoma from integration) in one Australian programme that informs design. The proposal is a head-to-head programme establishing non-viral manufacturing as the default for new autologous and allogeneic CAR-T, with integration-site safety monitoring as a shared standard.
One of the most cited reviews Europe PMC returns for CD19 in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for CD19 in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One bottleneck page and 22 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited reviews Europe PMC returns for CD19 in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials, The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19, SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies, Study of Out of Specification for Tisagenlecleucel.
Shares ZUMA-1, ZUMA-7, CD19, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
Shares ZUMA-1, ZUMA-7, Manufacturing cost and time for living and radioactive medicines, CD19.
Shares Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.